Adopting Innovative Trial design & Endpoints in High-risk MASLD
- Positive changes in the regulatory landscape of non-invasive tests, pushing the boundaries and reducing the need for invasive liver biopsies.
- The concept of High-risk MASLD
- The innovative phase 3 trial design of Lilly’s SYNERGY-Outcomes trial; mimicking clinical practice, streamline the entire development process and lower the cost of bringing a drug to approval while improving recruitment and retention